Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).

Antiviral therapy - 1 Jan 2012

Bourlière Marc, Ouzan Denis, Rosenheim Michel, Doffoël Michel, Marcellin Patrick, Pawlotsky Jean-Michel, Salomon Laurence, Fagnani Francis, Rouanet Stéphanie, Pinta Alexandrina, Vray Muriel

Abstract excerpt

BACKGROUND: The aim of this study was to document in real life the characteristics and management of hepatitis C patients treated with pegylated interferon-α2a and ribavirin, and the efficacy of treatment (sustained virological response [SVR]). METHODS: This observational study enrolled hepatitis C patients initiating pegylated interferon-α2a and ribavirin treatment. RESULTS: A total of 2,066 patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 22267474
DOI: 10.3851/IMP1935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).PMID 22267474Read ↗

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Semantic proximity Read ↗

Hepatitis C: efficacy and safety in real life.Semantic proximity Read ↗

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.Semantic proximity Read ↗

Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.Semantic proximity Read ↗

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis.Semantic proximity Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).Semantic proximity Read ↗

Hepatitis C: How Good Are Real-Life Data and Do Generics Work.Semantic proximity Read ↗

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.